Literature DB >> 12557751

Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells.

Yoshitaka Kumon1, Takanori Hosokawa, Tadashi Suehiro, Yukio Ikeda, Jean D Sipe, Kozo Hashimoto.   

Abstract

The human serum amyloid A (SAA) protein family is subclassified as acute phase SAA (A-SAA), which comprises the SAA1 and SAA2 allelic variants, and constitutive SAA (C-SAA), which is the SAA4 isoform. Extrahepatic production of A-SAA occurs in many organs and tissues of the body, including smooth muscle cells (SMC) of the aorta. A-SAA has been shown to act locally as a chemoattractant for neutrophils, monocytes and lymphocytes via the N-formyl peptide receptor-like (fPRL1). In order to gain further understanding of the physiological significance of local production of A-SAA by SMC, the effect of exogenous A-SAA on the in vitro migration of human aortic SMC was investigated. Increased SMC migration in the presence of A-SAA was detectable after six hours and continued to increase up to 24 hours after incubation. The increased migration was dose-dependent over the concentration range 10 to 100 micrograms/ml. The mode of A-SAA stimulated SMC migration was by chemotaxis not chemokinesis. Exogenous constitutive SAA (C-SAA) did not affect SMC migration. Stimulation of SMC migration by A-SAA was inhibited by both polyclonal and monoclonal antibodies to human SAA1 and also by the inhibitors of fPRL1 signaling, wortmannin, bisindolylmaleimide and pertussis toxin. The results herein indicate that A-SAA, but not C-SAA, may serve as an autocrine factor to influence SMC migration in situations of aortic tissue injury and inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12557751     DOI: 10.3109/13506120209114099

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  7 in total

1.  A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A.

Authors:  Ronan Hugh Mullan; Jennifer McCormick; Mary Connolly; Barry Bresnihan; Douglas James Veale; Ursula Fearon
Journal:  Am J Pathol       Date:  2010-03-19       Impact factor: 4.307

2.  Exocytosis of Neutrophil Formyl peptide receptor-like 1 (fPRL1) results in downregulation of cytoplasmic fPRL1 in patients with purulent dermatitis.

Authors:  Eiji Ohara; Yoshitaka Kumon; Toshihiro Kobayashi; Hiroaki Takeuchi; Tetsuro Sugiura
Journal:  Clin Vaccine Immunol       Date:  2007-04-25

Review 3.  The cytokine-serum amyloid A-chemokine network.

Authors:  Mieke De Buck; Mieke Gouwy; Ji Ming Wang; Jacques Van Snick; Paul Proost; Sofie Struyf; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

4.  Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner.

Authors:  Patricia G Wilson; Joel C Thompson; Nancy R Webb; Frederick C de Beer; Victoria L King; Lisa R Tannock
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

Review 5.  Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults.

Authors:  Mieke De Buck; Mieke Gouwy; Ji Ming Wang; Jacques Van Snick; Ghislain Opdenakker; Sofie Struyf; Jo Van Damme
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1.

Authors:  Sara Abouelasrar Salama; Mirre De Bondt; Mieke De Buck; Nele Berghmans; Paul Proost; Vivian Louise Soares Oliveira; Flavio A Amaral; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Front Immunol       Date:  2020-05-14       Impact factor: 7.561

7.  Serum amyloid A-containing HDL binds adipocyte-derived versican and macrophage-derived biglycan, reducing its antiinflammatory properties.

Authors:  Chang Yeop Han; Inkyung Kang; Mohamed Omer; Shari Wang; Tomasz Wietecha; Thomas N Wight; Alan Chait
Journal:  JCI Insight       Date:  2020-09-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.